NexImmune’s NEXI-003 Gets IND Clearance From FDA; Stock Jumps 25%

Shares of NexImmune, Inc. (NEXI) jumped over 25% in extended trading session on Thursday after the clinical-stage biotechnology company announced that it received IND clearance for its first cellular therapy product candidate addressing solid tumors

NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), is being developed for patients with relapsed or refractory human papillomavirus (HPV)-related cancers.

The IND clearance enables commencement of a clinical trial to evaluate NEXI-003 in patients with relapsed or refractory human papillomavirus (HPV)-related cancers.

An Investigational New Drug Application (IND) is a request from a clinical study sponsor to obtain authorization from the Food and Drug Administration (FDA) to administer an investigational drug or biological product to humans.

NEXI closed Thursday’s trading at $1.47, down $0.11 or 6.96%, on the Nasdaq. The stock, however, gained $0.37 or 25.17%, in the after-hours trading.

For More Such Health News, visit rttnews.com

Opinion | Why Markets Shrugged Off Bad Inflation News

Send any friend a story

As a subscriber, you have 10 gift articles to give each month. Anyone can read what you share.

By Paul Krugman

Opinion Columnist

Opinion | Americans Are Hungry for Change, So Get Ready for More Turmoil

Send any friend a story

As a subscriber, you have 10 gift articles to give each month. Anyone can read what you share.

By David Brooks

Opinion Columnist

Drägerwerk Q2 Preliminary Net Sales Down; Confirms FY Guidance

Drägerwerk AG & Co. KGaA (DRWKF.PK) reported that its preliminary net sales for the second quarter decreased 24.7 percent, net of currency effects, to around 653 million euros from the prior year.

But quarterly order intake rose by 7.6 percent, net of currency effects, to around 822 million euros from the previous year.

EBIT was about negative 77 million euros compared to positive 80.3 million euros in the prior year. The main reasons for the negative EBIT were the decline in sales and the lower gross margin.

The company expects a significant recovery in business development in the second half of the year. The expectation is based on the high order backlog and an expected improvement of the delivery situation.

The company therefore confirmed the forecast for the full year 2022. Accordingly, the company continues to expect a decline in net sales of between -5.0 and -9.0 percent (net of currency effects) and an EBIT margin of between 1.0 and 4.0 percent. It remains likely that the lower end of the range will be achieved in each case.

The full results for the first six months of the fiscal year will be published on July 28, 2022.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

John Deere Recalls Lawn Tractors

Agricultural machinery and equipment maker Deere & Co. is recalling certain John Deere lawn tractors due to crash and injury risks, the U.S. Consumer Product Safety Commission said.

The recall involves John Deere lawn tractors, models X380 and X390. About 160 units were sold in the United States and about 30 were sold in Canada.

The tractors are green and yellow. The tractors, manufactured in the U.S., were sold at John Deere dealers nationwide and online at John Deere.com from April 2022 through May 2022 for between $5,000 and $6,300.

According to the agency, the wheel hubs were not manufactured to specifications and can fail, causing the tractor to lose braking and propulsion. It could result in crash and injury hazards.

The recall was initiated after the Moline, Illinois-based firm received three reports of the lawn tractor not braking properly. One minor injury resulting in bruises and abrasions has been reported.

Consumers are asked to immediately stop using the recalled lawn tractors and contact an authorized John Deere dealer for a free repair.

Man With Incredible Beard Desperately Needs Kidney

Maybe mine?

Send any friend a story

As a subscriber, you have 10 gift articles to give each month. Anyone can read what you share.

By Julia Brown-Farley

Ericsson Gets Final Regulatory Approval From CFIUS To Acquire Vonage Holdings

Telecom major Ericsson (ERIC) said on Friday that it has received necessary approval from the Committee on Foreign Investments in the U.S. or CFIUS to complete the acquisition of Vonage Holdings Corporation (VG), a cloud communications provider.

With this, the both parties have now received the final requisite approval to complete the proposed transaction, expected to be closed no later than July 21.

Last year, Ericsson had inked a deal to buy Vonage for an enterprise value of $21 per share or around $6.2 billion. The acquisition is projected to be added to Ericsson’s profit from 2024.

The telecom firm also expects the acquisition to further support its wireless enterprise across the globe, by providing its existing customers with an increased share of a market valued at $700 billion by 2030.

For the year to September 2021, Vonage had posted sales of $1.4 billion with an adjusted EBITDA margin of 14 percent.